Legal Representation
Attorney
Douglas A. Miro
USPTO Deadlines
Next Deadline
1697 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20240910)
Due Date
September 10, 2030
Grace Period Ends
March 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 14, 2025 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Feb 20, 2025 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Feb 19, 2025 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Dec 10, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Sep 10, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 10, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 1, 2024 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Jun 25, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 25, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 11, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jun 11, 2024 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Jun 5, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 17, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 9, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 9, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 9, 2024 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Apr 8, 2024 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Mar 20, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Mar 20, 2024 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Mar 1, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 29, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Nov 29, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Nov 29, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Oct 20, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 20, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 20, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 17, 2023 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Apr 22, 2023 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Apr 22, 2023 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Mar 1, 2023 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Feb 28, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 23, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 25, 2022 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Oct 21, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 20, 2022 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Biological materials or preparations for 3D printers, namely, bioinks, bioprinting kits comprised of collagen, biological printed tissues other than for medical or veterinary purposes; hydrogels for cell culture not for medical or veterinary purposes; hydrogels for cell growth not for medical or veterinary purposes; cell culture media other than for medical or veterinary use; nutritional agents for processing living cells other than for medical use, namely, cell culture media within a reservoir for growth factors; culture media for microbiology for laboratory use; reagents for scientific and medical research; synthetic peptides not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; synthetic peptide derivatives not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; cells other than for medical, veterinary or pharmaceutical use; cells or tissues in hydrogels other than for medical, veterinary or pharmaceutical use; biologically compatible polymers, specifically hydrogels used to produce polymer networks used in the manufacture of engineered living tissues for medical, scientific and non-scientific purposes, namely, tissue implants, organoids, tissue models; cell culture media for use in the biotechnological industry for laboratory use; cell culture media for use in non-medical research laboratories; biological preparations for use in cell culture, other than for medical and veterinary purposes; engineered living tissues and tissue arrays, namely, human and animal organs, connective tissue, epithelial tissue, muscular tissue and nervous tissue, and tissue arrays, for use in scientific and medical research; biologically compatible materials, specifically, hydrogels used to create polymeric networks used in the manufacture of living tissues for laboratory use; proteins in the form of raw materials for scientific and medical research
Class 002
Inks of biological origin for printers; inks of biological origin for 3D printers
Class 005
Hydrogels for medical, veterinary and pharmaceutical purposes for cellular biology applications; hydrogels for cell growth, cell growth and transplantation, assays based on cells, cancer cell research, regenerative medicine, stem cell growth and drug delivery for medical use; hydrogels for cell culture for medical, veterinary and pharmaceutical purposes; hydrogels for cell growth for medical, veterinary and pharmaceutical purposes; cell culture media for medical use; nutritional agents for processing living cells, namely, cell culture media growth factors contained within a reservoir; synthetic peptides for the treatment of degenerated hard and soft tissues; synthetic peptide derivativesfor the treatment of degenerated hard and soft tissues; cells for medical, veterinary and pharmaceutical use; cells or tissues in hydrogels for medical, veterinary or pharmaceutical use; pharmaceutical preparations for use in 3D bio-printing of tissues and organs; pharmaceutical preparations with other materials and ingredients for use in 3D bio-printing of tissues and organs; regenerative tissue being pharmaceutical preparations for hard and soft tissue regeneration; cells for medical use; allogeneic human tissue; living cells for medical use; implants containing living tissue; implantable living tissue materials for use in guided tissue regeneration; skin grafts; surgical implants formed by living tissue; surgical implants of living tissues derived from stem cells; transdermal patches for the creation of skin for prostheses and skin grafts; living tissue for transplants; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, epithelial, muscular, and nervous tissues and organs, for medical purposes; biological molecules being implants comprising living tissue to assist in tissue engineering, namely, hard and soft tissue regeneration; hemostatic gel matrix preparations for wound treatment; natural biomaterials for the growth of bones, blood and tissues for medical purposes; pharmaceutical products for the regeneration of tissues, for the repair of tissues, for the treatment of tissues, whether human or animal, namely, 3D implants for hard and soft tissue regeneration combining bioinks and biological materials; pharmaceutical preparations for the treatment of diseases of bones, cartilages, blood vessels, nerve cell degeneration, tendon and ligament degeneration, retinal degeneration, kidney degeneration; soft tissue degenerations, for diseases with abnormal cell growth, namely, formulated bioinks for hard and soft tissue regeneration combining bioinks and biological materials with a pharmaceutical effect; natural biomaterial for bone filling; natural biomaterial for cartilage filling; biological tissue cultures for medical use; biological tissue cultures for medical purposes; biological tissue grafts; bone and skin biological tissues impregnated with oxygen lines for tissue constructs applicable for increasing the cell survival in tissue intended for subsequent implants; gene therapy products, namely, genetically modified tissues for the transplant thereof; implantable stents composed primarily of living tissue to maintain the structure of the tissue; natural biomaterial for bone and tissue growth for medical purposes
Classification
International Classes
001
002
005